Cargando…
Prevalence and Subtypes of Mild Cognitive Impairment in Parkinson’s Disease
The current study examined the prevalence and subtypes of Mild Cognitive Impairment (MCI) in an Australian sample of people with Parkinson’s Disease (PD). Seventy participants with PD completed neuropsychological assessments of their cognitive performance, using MDS Task Force Level II diagnostic cr...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030649/ https://www.ncbi.nlm.nih.gov/pubmed/27650569 http://dx.doi.org/10.1038/srep33929 |
_version_ | 1782454716101296128 |
---|---|
author | Lawrence, Blake J. Gasson, Natalie Loftus, Andrea M. |
author_facet | Lawrence, Blake J. Gasson, Natalie Loftus, Andrea M. |
author_sort | Lawrence, Blake J. |
collection | PubMed |
description | The current study examined the prevalence and subtypes of Mild Cognitive Impairment (MCI) in an Australian sample of people with Parkinson’s Disease (PD). Seventy participants with PD completed neuropsychological assessments of their cognitive performance, using MDS Task Force Level II diagnostic criteria for PD-MCI. A cut-off score of less than one standard deviation (SD) below normative data determined impaired performance on a neuropsychological test. Of 70 participants, 45 (64%) met Level II diagnostic criteria for PD-MCI. Among those with PD-MCI, 42 (93%) were identified as having multiple domain impairment (28 as amnestic multiple domain and 14 as nonamnestic multiple domain). Single domain impairment was less frequent (2 amnestic/1 nonamnestic). Significant differences were found between the PD-MCI and Normal Cognition groups, across all cognitive domains. Multiple domain cognitive impairment was more frequent than single domain impairment in an Australian sample of people with PD. However, PD-MCI is heterogeneous and current prevalence and subtyping statistics may be an artifact of variable application methods of the criteria (e.g., cut off scores and number of tests). Future longitudinal studies refining the criteria will assist with subtyping the progression of PD-MCI, while identifying individuals who may benefit from pharmacological and nonpharmacological interventions. |
format | Online Article Text |
id | pubmed-5030649 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-50306492016-09-26 Prevalence and Subtypes of Mild Cognitive Impairment in Parkinson’s Disease Lawrence, Blake J. Gasson, Natalie Loftus, Andrea M. Sci Rep Article The current study examined the prevalence and subtypes of Mild Cognitive Impairment (MCI) in an Australian sample of people with Parkinson’s Disease (PD). Seventy participants with PD completed neuropsychological assessments of their cognitive performance, using MDS Task Force Level II diagnostic criteria for PD-MCI. A cut-off score of less than one standard deviation (SD) below normative data determined impaired performance on a neuropsychological test. Of 70 participants, 45 (64%) met Level II diagnostic criteria for PD-MCI. Among those with PD-MCI, 42 (93%) were identified as having multiple domain impairment (28 as amnestic multiple domain and 14 as nonamnestic multiple domain). Single domain impairment was less frequent (2 amnestic/1 nonamnestic). Significant differences were found between the PD-MCI and Normal Cognition groups, across all cognitive domains. Multiple domain cognitive impairment was more frequent than single domain impairment in an Australian sample of people with PD. However, PD-MCI is heterogeneous and current prevalence and subtyping statistics may be an artifact of variable application methods of the criteria (e.g., cut off scores and number of tests). Future longitudinal studies refining the criteria will assist with subtyping the progression of PD-MCI, while identifying individuals who may benefit from pharmacological and nonpharmacological interventions. Nature Publishing Group 2016-09-21 /pmc/articles/PMC5030649/ /pubmed/27650569 http://dx.doi.org/10.1038/srep33929 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Lawrence, Blake J. Gasson, Natalie Loftus, Andrea M. Prevalence and Subtypes of Mild Cognitive Impairment in Parkinson’s Disease |
title | Prevalence and Subtypes of Mild Cognitive Impairment in Parkinson’s Disease |
title_full | Prevalence and Subtypes of Mild Cognitive Impairment in Parkinson’s Disease |
title_fullStr | Prevalence and Subtypes of Mild Cognitive Impairment in Parkinson’s Disease |
title_full_unstemmed | Prevalence and Subtypes of Mild Cognitive Impairment in Parkinson’s Disease |
title_short | Prevalence and Subtypes of Mild Cognitive Impairment in Parkinson’s Disease |
title_sort | prevalence and subtypes of mild cognitive impairment in parkinson’s disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030649/ https://www.ncbi.nlm.nih.gov/pubmed/27650569 http://dx.doi.org/10.1038/srep33929 |
work_keys_str_mv | AT lawrenceblakej prevalenceandsubtypesofmildcognitiveimpairmentinparkinsonsdisease AT gassonnatalie prevalenceandsubtypesofmildcognitiveimpairmentinparkinsonsdisease AT loftusandream prevalenceandsubtypesofmildcognitiveimpairmentinparkinsonsdisease |